Stay updated on TAPUR Study: Targeted Drug Clinical Trial
Sign up to get notified when there's something new on the TAPUR Study: Targeted Drug Clinical Trial page.

Latest updates to the TAPUR Study: Targeted Drug Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedAdded arms for Dabrafenib plus Trametinib (Group 26) and Fam-trastuzumab deruxtecan-nxki (TDxD) with related mutations and drugs, expanding targeted therapy options; removed several arms (Atezolizumab+PHESGO, Pembrolizumab, Entrectinib, Larotrectinib, ROS1/NTRK groups) and updated the brain metastases exclusion, affecting eligibility and treatment choices.SummaryDifference0.8%

- Check18 days agoChange DetectedRevision label updated from v3.4.0 to v3.4.1 at the bottom of the page. This is a minor UI/text update with no impact on study information.SummaryDifference0.0%

- Check32 days agoChange DetectedShow glossary feature added. Multiple contact entries and site locations updated, including names, phone numbers, emails, and addresses, and some outdated contacts removed.SummaryDifference0.9%

- Check39 days agoChange DetectedRevision: v3.3.4 is now displayed; Revision: v3.3.3 has been removed.SummaryDifference0.0%

- Check67 days agoChange DetectedLocations section updated with a comprehensive list of participating sites by state and the page revision updated to v3.3.3.SummaryDifference0.6%

- Check89 days agoChange DetectedRevision history now shows v3.3.2 added and v3.3.1 removed.SummaryDifference0.0%

Stay in the know with updates to TAPUR Study: Targeted Drug Clinical Trial
Enter your email address, and we'll notify you when there's something new on the TAPUR Study: Targeted Drug Clinical Trial page.